ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2026
Guanfacine as a Treatment Option for Persistent Mental Restlessness and Deliberate Self-harm Thoughts in a Patient with Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Borderline Personality Disorder, and Post-traumatic Stress Disorder: Case Report.
Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deliberate self-harm (DSH) in adolescents presents a significant clinical challenge, particularly when compounded by comorbidities such as attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), borderline personality disorder (BPD), and post-traumatic stress disorder (PTSD). We describe a case of a 16-year-old transgender Māori male with ADHD, ASD traits, BPD, and PTSD, who presented with persistent mental restlessness experienced as intrusive DSH ideation. He had limited benefit and intolerable side effects with atomoxetine but responded to guanfacine modified-release. Guanfacine modified-release (1 mg nocte) treatment coincided with a marked reduction in mental restlessness and intrusive DSH ideation. During the follow-up period, there was a decrease in acute healthcare utilisation. Then the patient self-ceased guanfacine, coinciding with a return of DSH ideation and behaviours. We hypothesise that the ADHD-related mental restlessness was associated with intrusive DSH ideation; amelioration of mental restlessness and self-harm ideation by guanfacine can be interpreted as the 'dechallenge' phase of a 'challenge-dechallenge' natural experiment. This case provides novel evidence for the potential therapeutic role of guanfacine in mitigating persistent self-harm thoughts, via modulation of mental restlessness and impulsivity. Our observation provides preliminary evidence of the potential benefit of guanfacine in treating DSH, in the context of patients with co-occurring cognitive rigidity, trauma exposure, and emotional dysregulation. This case aligns with emerging evidence for the efficacy of guanfacine for ASD and trauma-related disorders, but is the first - in the existing literature - for ADHD and trauma history in an adolescent with BPD and transgender intersectionality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.